Sentiment-Signal
22,5
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Unternehmen & Branche
| Name | RELMADA THERAPEUTICS, INC. |
|---|---|
| Ticker | RLMD |
| CIK | 0001553643 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 521,5 Mio. USD |
| Beta | 0,45 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -57,385,163 | -1.45 | 94,003,471 | 86,512,013 | |
| 2025-09-30 | 10-Q | -10,091,496 | -0.30 | 14,876,244 | 9,465,539 | |
| 2025-06-30 | 10-Q | -9,866,442 | -0.30 | 21,116,144 | 15,949,481 | |
| 2025-03-31 | 10-Q | -17,559,465 | -0.58 | 27,679,417 | 22,440,491 | |
| 2024-12-31 | 10-K | -79,979,354 | -2.65 | 45,817,818 | 35,521,961 | |
| 2024-09-30 | 10-Q | -21,725,970 | -0.72 | 55,724,505 | 47,625,182 | |
| 2024-06-30 | 10-Q | -17,768,122 | -0.59 | 71,028,476 | 61,491,628 | |
| 2024-03-31 | 10-Q | -21,828,126 | -0.72 | 84,408,164 | 72,046,331 | |
| 2023-12-31 | 10-K | -98,791,746 | -3.28 | 97,552,042 | 85,357,242 | |
| 2023-09-30 | 10-Q | -22,002,058 | -0.73 | 109,148,853 | 100,726,635 | |
| 2023-06-30 | 10-Q | -25,302,954 | -0.84 | 122,038,221 | 111,335,755 | |
| 2023-03-31 | 10-Q | -26,321,576 | -0.87 | 135,566,449 | 125,469,192 | |
| 2022-12-31 | 10-K | -157,043,823 | -5.30 | 152,905,179 | 140,436,302 | |
| 2022-12-31 | 10-Q | -39,745,783 | -1.40 | 152,905,179 | 140,436,302 | |
| 2022-09-30 | 10-Q | -39,418,707 | -1.31 | 187,122,008 | 166,344,855 | |
| 2022-06-30 | 10-Q | -39,934,968 | -1.33 | 215,772,485 | 196,851,331 | |
| 2022-03-31 | 10-Q | -39,745,783 | 225,807,609 | 210,398,132 | ||
| 2021-12-31 | 10-K | -125,751,809 | -7.16 | 223,325,811 | 208,264,886 | |
| 2021-09-30 | 10-Q | -42,606,191 | -2.44 | 90,934,441 | 72,687,091 | |
| 2021-06-30 | 10-Q | -26,551,944 | -1.56 | 110,769,300 | 96,852,557 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | Shenouda Maged | Officer, Chief Financial Officer | Open Market Purchase | 11,665 | 4.12 | 48,059.80 | +27,3% | |
| 2025-12-15 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 27,500 | 4.12 | 113,300.00 | +64,3% | |
| 2025-11-05 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 272,500 | 2.20 | 599,500.00 | +340,0% | |
| 2025-11-05 | Kelly Paul Edward | Director, Officer, Chief Operating Officer | Open Market Purchase | 90,000 | 2.20 | 198,000.00 | +112,3% | |
| 2025-11-05 | Shenouda Maged | Officer, Chief Financial Officer | Open Market Purchase | 500,000 | 2.20 | 1,100,000.00 | +623,9% | |
| 2025-11-05 | Ence Chuck | Officer, CAO and COO | Open Market Purchase | 136,000 | 2.20 | 299,200.00 | +169,7% | |
| 2025-08-28 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 55,976 | 0.74 | 41,422.24 | +23,5% | |
| 2025-08-27 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 129,455 | 0.67 | 86,734.85 | +49,2% | |
| 2025-08-26 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 80,545 | 0.62 | 49,937.90 | +28,3% | |
| 2025-05-20 | Shenouda Maged | Officer, Chief Financial Officer | Open Market Purchase | 60,000 | 0.52 | 31,422.00 | +17,8% | |
| 2025-05-20 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 147,686 | 0.56 | 82,246.33 | +46,6% | |
| 2025-05-19 | Shenouda Maged | Officer, Chief Financial Officer | Open Market Purchase | 90,000 | 0.49 | 43,686.00 | +24,8% | |
| 2025-05-19 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 30,000 | 0.50 | 14,994.00 | +8,5% | |
| 2025-05-16 | Shenouda Maged | Officer, Chief Financial Officer | Open Market Purchase | 50,000 | 0.44 | 22,100.00 | +12,5% | |
| 2025-05-16 | Ence Chuck | Officer, CA and CO | Open Market Purchase | 228,961 | 0.45 | 103,330.10 | +58,6% | |
| 2025-05-16 | TRAVERSA SERGIO | Director, Officer, Chief Executive Officer | Open Market Purchase | 172,314 | 0.45 | 77,472.37 | +43,9% | |
| 2025-05-16 | Kelly Paul Edward | Director, Officer, Chief Operating Officer | Open Market Purchase | 200,000 | 0.43 | 86,060.00 | +48,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.